Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

542 TIOPRONIN
(1990): Kurumaji Y+, JDermatol(Tokio) 17, 176
(1988): Kawabe Y+, JDermatol(Tokio) 15, 434 (bullous)
Lupus erythematosus
(1986): Katayama I+, JDermatol(Tokio) 13, 151
Pemphigus (5%)
(1994): Verdier-Sevrain S+, Br J Dermatol 130, 238
(1990): Meunier L+, Ann Dermatol Venereol (French) 117, 959
(1990): Sany J+, Rev Rhum Mal Osteoartic (French) 57, 105
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
(5.8%)
(1987): Enjolras O+, Ann Dermatol Venereol (French) 114, 25
Pemphigus erythematodes
(1982): Alinovi A+, Acta Derm Venereol (Stockh) 62, 452
Pemphigus foliaceus
(1983): Lucky PA+, JAmAcadDermatol8, 667
Pemphigus vulgaris
(1984): Trotta F+, Scand J Rheumatol 13(1), 93
Photosensitivity (1%)
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
(1.5%)
Pityriasis rosea (5%)
(1990): Sany J+, Rev Rhum Mal Osteoartic (French) 57, 105
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
(5.8%)
Pruritus
Rash (sic)
Side effects (sic) (27%)
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
(27.5%)
Toxic epidermal necrolysis
Urticaria
Wrinkling (sic)
Mucosal
Mucocutaneous reactions (sic)
(1990): Sany J+, Rev Rhum Mal Osteoartic (French) 57, 105
(32.8%)
Oral lesions (4%)
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
(4.4%)
(1984): Shichiri M+, Arch Intern Med 144, 89
Oral ulceration
(2000): Madinier I+, Ann Med Interne (Paris) (French) 151, 248
Stomatitis
(1990): Sany J+, Rev Rhum Mal Osteoartic (French) 57, 105
(1988): Sigaud M+, Rev Rhum Mal Osteoartic (French) 55, 467
Xerostomia
Hair
Hair – alopecia
(1990): Sany J+, Rev Rhum Mal Osteoartic (French) 57, 105
Hair – hypertrichosis
(1993): Arnaud M+, Joint Bone Spine Dis 60, 548
Other
Myalgia/Myositis/Myopathy/Myotoxicity
(1988): Menkes CJ+, Presse Med (French) 17, 1156
TIOTROPIUM
Trade name: Spiriva (Boehringer Ingelheim)
Indications: Bronchospasm (associated with COPD)
Category: Anticholinergic; Muscarinic antagonist
Half-life: 5–6 days
Clinically important, potentially hazardous interactions
with: None
Reactions
Skin
Allergic reactions (sic) (1–3%)
Angioedema (3%)
Hypersensitivity
Infections
Myalgia/Myositis/Myopathy/Myotoxicity (4%)
Upper respiratory infection (41%)
(2006): Kesten S+, Chest 130(6), 1695
TIPRANAVIR
Trade name: Aptivus (Boehringer Ingelheim)
Indications: Antiretroviral treatment of HIV-1
Category: Protease inhibitor, HIV; Sulfonamide
Half-life: 4.8–6.0 hours
Clinically important, potentially hazardous interactions
with: amiodarone, bepridil, dihydroergotamine, ergotamine,
flecainide, lovastatin, midazolam, pimozide, propafenone,
quinidine, rifampin, simvastatin, St John’s wort, triazolam
Skin
Exanthems (